Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Intervacc announces changes in the Nomination Committee
Stockholm, December 21, 2023 – Intervacc AB (publ) announces that the company and the chairman of the board have been informed that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden have resigned from the Nomination...The National Equestrian Centre at Flyinge to host European expert meeting on the use of vaccination to prevent strangles in horses
Stockholm, December 11, 2023 – European experts on strangles, a highly contagious and serious infectious disease affecting horses, will on December 13th meet at the National Equestrian Centre at Flyinge to share experiences on the use of vaccination to prevent...Report from Extraordinary General Meeting in Intervacc
Stockholm, November 23, 2023 – Intervacc AB (publ) has at the request of a group of shareholders, which together control not less than one-tenth of all shares in the company, on 23 November 2023 held an Extraordinary General Meeting (“EGM”), at which the...U.S. patent approval for Intervacc’s vaccine against infections caused by Streptococcus suis
Stockholm, November 22, 2023 – Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc’s patent application in the United States for a vaccine against Streptococcus suis infections in pigs. The U.S....Interim report January – September 2023
Sales of Strangvac® are still low, but higher sales have been noted in recent months. The Group in summary 01/07/23 01/07/22 01/01/23 01/01/22 Full year -30/09/23 -30/09/22 -30/09/23 -30/09/22 2022...Nyhetstjänster
